Home
MEET US IN PARK CITY, UT
Registration & Housing Now Available
March 1-4, 2025
HCNMC will be in-person for the 2025 High Country Nuclear Medicine Conference in Park City, UT.
The HCNMC is committed to ensuring that appropriate health and safety protocols are in place for this event. We will follow all Centers for Disease Control and Prevention (CDC) safety protocols and recommendations and will comply with all federal, state and local regulations.
High Country continues to attract and blend experts from academia and industry, with leaders in medical specialties, the regulatory agencies and health care researchers in an informal setting to facilitate dialog and an exchange of ideas. The meeting consists of six to seven hours of structured sessions per day (8 sessions total). In between sessions, roundtable discussions will be held and there are ample opportunities for independent meetings and networking.
Thank you to our 2025 Sponsors!
Title Sponsor
Life Molecular Imaging (LMI) is an international pharma company dedicated to developing and offering novel, cutting-edge PET radiopharmaceuticals. LMI’s mission is to pioneer innovative PET tracers that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.
Featured Sponsors
At Curium, we have a singular focus – to develop, manufacture and supply world-class radiopharmaceutical products around the globe. We strive to innovate further in nuclear diagnostics and therapies so we can enhance the lives of people with cancer.
Bracco Diagnostics Inc. (BDI), the U.S.-based subsidiary of Bracco Imaging SpA, and part of the Bracco Group, is a leader in innovative imaging agents. Bracco offers a product and solution portfolio for all key diagnostic imaging modalities: X-Ray Imaging, Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers.
Bracco nuclear medicine offers specialty radiopharmaceuticals for cardiac PET and hepatobiliary imaging. A decades-long legacy of excellence through research, innovation and clinical expertise has earned Bracco a reputation as the market leader in cardiac PET imaging.
Find out how our solutions, expertise and experience can help you and your patients.
Lantheus is the leading radiopharmaceutical-focused company with proven expertise in developing, manufacturing, and commercializing pioneering diagnostic and therapeutic products and artificial intelligence (AI) solutions.
Nusano is a privately held physics company committed to bringing stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market. Nusano’s proprietary ion source is smaller and more efficient than existing production methods. This results in significantly greater yields and allows for the simultaneous manufacturing of multiple radioisotopes. Nusano’s technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development. The company’s state-of-the-art production facility opens in 2025 in West Valley City, Utah.
RayzeBio, a Bristol Myers Squibb company, is focused on improving survival of people with cancer by harnessing the power of targeted radioisotopes.
Supporter Sponsors
Blue Earth Diagnostics, a Bracco company, is an industry leader in precision imaging radiopharmaceuticals to help diagnose, stage and monitor cancer for patients. Its products include PET diagnostic imaging agents for prostate cancer and an expanding portfolio that spans a variety of disease states.
CDL Nuclear Technologies is a leading provider of innovative cardiac imaging solutions and comprehensive services. We specialize in Complete Cardiac PET/CT suite Buildouts, On-Demand Mobile Rubidium-82, and Mobile Cardiac PET/CT, offering tailored solutions for healthcare providers. Our expertise ensures precise diagnostics, enhanced patient care, and seamless integration for cardiology practices nationwide.
Clarity Pharmaceuticals is a global leader in the development of next-generation diagnostic and therapeutic radiopharmaceuticals with its Targeted Copper Theranostic (TCT) platform of products that utilize the “perfect pairing” of copper-64 for imaging and copper-67 for therapy.
Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Switzerland, the award-winning medical device company was founded in 2018 as an ETH Zurich spin-off. NeuroLF® – the company’s first device – is an ultra-compact brain Positron Emission Tomography (PET) system which has applications in the diagnosis of most neurological diseases with emphasis on Alzheimer’s Dementia.
SHINE Technologies, based in Janesville, Wisconsin, is pioneering next-generation fusion technology for medical isotope production. Specializing in n.c.a. lutetium-177 and soon, molybdenum-99, SHINE aims to revolutionize cancer treatment and diagnostics. Their innovative fusion-based approach drives advancements across multiple sectors, including healthcare and sustainable energy solutions.
